Online inquiry

IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13823MR)

This product GTTS-WQ13823MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13823MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14982MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ15120MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ8986MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ11161MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ541MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ4670MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ3312MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ1350MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-806
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW